09 Aug Ray Therapeutics
Peter Francis, M.D., Ph.D., Chief Scientific Officer, Chief Medical Officer
Oct. 11 | 11:15am | Rentschler ATMP Ballroom
San Francisco, CA
Ray Therapeutics (RayTx) is a Bay Area CIRM-funded biotechnology company developing next generation optogenetic therapies for vision restoration in patients with retinal blindness. In May 2023, RayTx closed a $100M series A. Early-stage clinical trials with the first iteration of optogenetic gene therapies have provided strong signals of biological activity. Building on this foundation, Ray Therapeutics (RayTx) has bioengineered a highly sensitive optogenetic protein, ChRown, which for the first time has optimal characteristics for human vision. Delivered using a AAV vector variant developed for low dose intravitreal delivery to the retina, RayTx’s assets, RTx-015, -16 & -021 have the promise to realize the full potential of visual optogenetics and provide patients higher visual function than previously contemplated. ChRown is also sensitive enough to be active in ambient lighting conditions without the use of light-intensifying “goggles”. RayTx will initiate clinical trials within the next 6-12 months.